Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Multiplicom Launches Two New Diagnostic Kits

Published: Tuesday, June 03, 2014
Last Updated: Tuesday, June 03, 2014
Bookmark and Share
Company aims for strong growth in the rapidly expanding molecular diagnostic market.

Multiplicom NV has announced that it has achieved ISO 13485 accreditation, and is launching two new CE/IVD labeled DNA mutation detection kits for Cystic Fibrosis (CF) and Familial Mediterranean Fever (FMF), genetics diseases with a high carrier rate.

Dr Dirk Pollet, CEO of Multiplicom, said: “Having ISO 13485 accreditation establishes Multiplicom as a reliable supplier of diagnostic kits to clinical labs as well as to the major diagnostic companies worldwide. All Multiplicom MASTR products have a uniform protocol, require only standard equipment and are compatible with MPS equipment from Roche, Illumina and Thermo Fisher. The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in the routine clinical labs, enabling personalized medicine.”

Multiplicom was recently awarded ISO 13485:2003 and ISO 13485:2012 certification for “Design, development, manufacturing and distribution of in vitro molecular diagnostic test kits used for the identification of genomic and somatic variants.”

This week, at the European Society for Human Genetics in Milan, Multiplicom has announced the launch of two new CE/IVD labeled MASTR kits, for the comprehensive detection of mutations associated with CF in June and FMF in July. With these new CE/IVD labeled kits Multiplicom aims to take a significant market share in the screening markets for both diseases.

Multiplicom is operating in an area of rapid growth. The European MPS diagnostic market is expected to grow from €20M in 2012 to >€2,000M in 2018 (CAGR% >100%) within a worldwide market of >€6,000M in 2018.

Based on its success in Europe, with expected sales in 2014 of > €6M (CAGR%>100%), the ISO 13485 accreditation and the launch of new products for both genomic and somatic mutations, Multiplicom is now in pole position for additional growth in other major territories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Multiplicom Appoints Board Chairman
Appointment of Dr Ian Gilham as Chairman of the Board of Directors.
Thursday, June 27, 2013
Multiplicom’s BRCA MASTR™ Dx Test Accredited with CE/IVD Mark
BRCA MASTR Dx will be shipped throughout Europe from September 2012.
Wednesday, June 20, 2012
Multiplicom Receives €200,000 Grant for Novel Non-Invasive Pre-Natal Test
IWT grant to support development of early aneuploidy detection during pregnancy.
Thursday, June 07, 2012
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Mothers Obesity Could be Passed on in mtDNA
Obesity can predispose offspring in multiple generations to metabolic problems.
New Imaging Method Reveals Nanoscale Details about DNA
Enhancement to super-resolution microscopy shows orientation of individual molecules, providing a new window into DNA’s structure and dynamics.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
Naked Mole Rat Exhibits “Extraordinary” Cancer Resistance
Scientists are getting closer to understanding the anti-cancer mechanism of the naked mole rat by making induced pluripotent stem cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!